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Abstract

Introduction: Individuals in early stages of Alzheimer’s disease are a targeted population for secondary prevention trials aimed at preserving normal cognition. Understanding within-person biomarker(s) change over time is critical for trial enrollment and design.
Methods: Longitudinal cerebrospinal fluid samples from the Alzheimer’s Disease Neuroimaging Initiative were assayed for novel markers of neuronal/synaptic injury (visinin-like protein 1, Ng, and SNAP-25)
and neuroinflammation (YKL-40) and compared with b amyloid 42, tau, and phospho-tau181. General
linear mixed models were used to compare within-person rates of change in three clinical groups (cognitively normal, mild cognitive impairment, and Alzheimer’s disease) further defined by b amyloid status.
Results: Levels of injury markers were highly positively correlated. Despite elevated baseline levels
as a function of clinical status and amyloid-positivity, within-person decreases in these measures were
observed in the early symptomatic, amyloid-positive Alzheimer’s disease group.
Discussion: Knowledge of within-person biomarker change will impact interpretation of biomarker
outcomes in clinical trials that are dependent on disease stage.
Ó 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
Clinical trials of potential disease-modifying therapies for
Alzheimer’s disease (AD) have failed to slow down cognitive
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decline in patients who have dementia or milder cognitive
symptoms (e.g., mild cognitive impairment [MCI]) [1]. Since
AD pathology begins to develop w20 years before cognitive
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decline (preclinical AD) [2,3], it is possible that trial
participants were too far along in the disease process for
such therapies to impact cognition. Therefore, individuals at
earlier stages, including the asymptomatic and preclinical
stage (defined by biomarkers), are now receiving intense
focus for secondary prevention trials aimed at preserving
normal cognitive function. Understanding the patterns of
biomarker(s) change over time, both in asymptomatic and
early symptomatic stages, is critical for defining where
individuals fall along the pathologic disease cascade.
Cross-sectional studies indicate that b amyloid (Ab)related biomarkers become abnormal first, followed by
markers of tau-related neuronal injury, both during the preclinical period [4]. Elevated injury markers in the presence of
amyloid-positivity then become a strong predictor of subsequent cognitive decline [5]. Interestingly, while regional brain
atrophy then ensues, with abnormality increasing with symptomatic progression [6], a recent, albeit small, study of individuals (n 5 37) from families at risk for developing autosomaldominant AD reported longitudinal decreases in cerebrospinal
fluid (CSF) levels of neuronal injury markers including total
tau (tTau), phospho-tau181 (pTau181), and visinin-like protein 1 (VILIP-1) in symptomatic mutation carriers [7], suggesting a slowing of acute neurodegenerative processes and/
or a decrease in the number of viable neurons contributing
to the pools of these markers in this later stage of the disease.
Regardless of the mechanism, if confirmed in an independent
cohort of persons developing late onset AD, such a pattern will
likely have an impact on interpretation of biomarker outcomes
in clinical trials that is dependent on the disease stage. To this
end, the present study evaluated the patterns of within-person
longitudinal change in a variety of standard (tTau and
pTau181) and novel (VILIP-1, neurogranin [Ng], and
synaptosomal-associated protein 25 [SNAP-25]) CSF
neuronal injury biomarker levels in individuals spanning the
full range of AD, including normal, preclinical AD, MCI
due to AD, and symptomatic AD, and a comparison of these
changes with regional brain atrophy and cognitive decline.

2. Methods
2.1. Alzheimer’s Disease Neuroimaging Initiative study
design
CSF Ab42, tTau, and pTau181 demographic, imaging,
and cognitive data were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (http://
adniloni.usc.edu). The ADNI was launched in 2003 as a
public–private partnership, led by Principal Investigator
Michael W. Weiner, MD. The primary goal of ADNI has
been to test whether serial magnetic resonance imaging
(MRI), biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. ADNI participants have been
recruited from more than 50 sites across the USA and Canada. Regional ethical committees of all institutions approved

of the study, and all participants provided written informed
consent. For up-to-date information, see www.adni-info.org.
2.2. Study participants
The ADNI cohort in the present study consisted of all
cognitively normal (CN) participants and those with MCI or
AD dementia (AD) with available CSF samples from at least
two visits as of April 2012. This cohort included 152 individuals across ADNI1, ADNI GO, and ADNI2 (n 5 56 CN,
n 5 73 MCI, and n 5 17 AD). Demographic and cognitive
data were downloaded in August 2015 and were collected
as described (adni.loni.usc.edu/methods/documents/). By
definition, individuals in the CN group all had a clinical dementia rating (CDR) score of 0 at the time of lumbar puncture
(LP) and a Mini–Mental State Examination (MMSE)
score  24. Individuals with MCI also scored 24 on the
MMSE but exhibited subjective memory loss (.1 standard
deviation [SD] below the normal mean of the delayed recall
of the Wechsler Memory Scale Logical Memory II), received
a CDR of 0.5, and preserved activities of daily living and the
absence of dementia. The AD group met the definition of
probable AD according to the criteria established by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related
Disorders Association [8] and had MMSE scores of 20–26
and CDRs of 0.5 or 1. Groups were designated by clinical
diagnosis at the time of initial available CSF sample in the
longitudinal cohort (defined herein as baseline).
2.3. ADNI clinical, CSF and imaging data
Scores for MMSE and Alzheimer’s Disease Assessment
Scale-cognitive 11 (ADAS11) and ADAS13 were downloaded from the LONI site in August 2015 via ADNIMerge
R Package. Values for CSF Ab42 (INNO-BIA AlzBio3; Fujirebio, Ghent, Belgium) were downloaded at the same time
from two data sets (UPENNBIOMK4 and UPENNBIOMK6)
and were used to define amyloid-positivity based on a published, autopsy-confirmed cutoff value (,192 pg/mL) [9].
For statistical analyses, values for Ab42, tTau, and pTau181
generated by a single lot number of the novel, fully automated, electrochemiluminescent ElecsysÒ immunoassays
(Roche Diagnostics, Basel, Switzerland) were downloaded
from the LONI site in March 2017 from a single data set (UPENNBIOMK9). The ElecsysÒ system aims to offer a fully
automated CSF biomarker test for AD capable of achieving
In Vitro Diagnostic capability and offers some improvements
over current Research Use Only assays including the
following: reduction in manual steps, improved precision
and accuracy both within labs and between labs, and
improved lot-to-lot reagent performance. The ElecsysÒ
Ab42 immunoassay in use is not a commercially available
In Vitro Diagnostic assay. It is an assay currently under development and used only for investigation purposes. The
measuring range of the assay is 200 (lower technical
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limit)—1700 (upper technical limit) pg/mL. The performance
of the assay beyond the upper technical limit has not been
formally established. Therefore, values above the upper technical limit have been truncated at 1700 pg/mL. In the present
study, baseline analyses excluded these data. Longitudinal
statistical analyses were run with and without these truncated
values and performed nearly identically.
MRI data for the left and right hippocampal (HP) volume
(white matter parcellation) and left and right entorhinal cortex
(EC) thickness, two regions known to be affected early in AD,
were also analyzed. EC thickness and HP volume were downloaded in November 2016 from the file UCSFFSL_02_01_16.
Acquisition of 1.5 Tesla MRI and data processing methods
are as described (adni.loni.usc.edu/methods/mri-analysis/).
Data were processed using FreeSurfer, version 4.4, and only
values that passed all quality control standards were included
in the analyses. Values for left and right HP and EC thickness
were added together to create a value for “total” HP volume
and EC thickness. In analyses evaluating potential effects of
ventricular volume on CSF biomarker concentrations, we
created a variable termed “ total ventricular volume” by summing left [ST37SV] and right [ST96SV] lateral ventricle, left
[ST30SV] and right [ST89SV] inferior lateral ventricle, and
third ventricle [ST127SFV] from the ADNI data set so to
best capture ventricular volume in its entirety.
2.4. Novel CSF analytes
Samples were analyzed for YKL-40 (also known as chitinase 3-like 1, a marker of gliosis/neuroinflammation) [10],
VILIP-1 (a neuronal calcium sensor protein and marker of
neuronal injury) [11], Ng (a postsynaptic protein and marker
of synaptic dysfunction) [12], and SNAP-25 (a presynaptic
protein and marker of synaptic dysfunction) [13]. YKL-40
was measured with a plate-based enzyme-linked immunoassay (MicroVue ELISA; Quidel, San Diego, CA) [14].
VILIP-1 [15,16], Ng [17,18], and SNAP-25 were measured
using microparticle-based immunoassays using the Singulex
(now part of EMD Millipore; Alameda, CA) Erenna system,
and employed antibodies developed in the laboratory of Dr.
Jack Ladenson at Washington University. All samples (each
on the same freeze/thaw cycle) were run in triplicate on a single lot number for VILIP-1, SNAP-25, and Ng and in duplicate
for YKL-40. Within-person longitudinal samples were run on
the same assay plate to reduce interplate and intraplate variability. Quality control for VILIP-1, SNAP-25, and Ng
included analysis of three internal standard CSF pools run
on each plate and two internal pools for YKL-40. See
Supplementary Text for assay details.
2.5. Statistical analysis
Because the study intent was to compare baseline
biomarker levels and their longitudinal change over time
in individuals who span the AD continuum (from no disease
[normal] to preclinical AD, to MCI due to AD, and to AD),
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participants in the three diagnostic categories (CN, MCI, and
AD) were further stratified into b amyloid-positive (Ab1)
versus b amyloid-negative (Ab2) at baseline based on the
published ADNI CSF Ab42 cutoff of , 192 pg/mL [9].
Baseline characteristics for the five resultant groups
(CN2, CN1, MCI2, MCI1, and AD1) were summarized
as mean (SD) for continuous variables or number (percentage) for categorical variables. Group differences among
the various measures were assessed using one-way analysis
of variance and post hoc Tukey tests. Correlations between
measures were assessed via Spearman correlation.
Biomarker concentrations, cognitive performance, and
MRI measures within individuals over time were compared
among the five groups (all AD individuals were Ab1) by general linear mixed models with random intercepts/slopes at the
subject level to allow estimation and comparison of withinperson rates of change [19]. In addition to the mean intercept
and slope for each group (unadjusted models), covariates
including age at baseline, apolipoprotein E (APOE) ε4 carriage, sex, education, and ventricular volume, their interactions
with subject groups on the intercepts and slopes, were also
included as fixed effects (see Supplementary Text). All general
linear mixed models assumed a subject-level random effect on
intercept and slope and were fitted using the maximum likelihood method. Statistical tests were based on the approximate F
or t-tests with denominator degrees of freedom approximated
by the Satterthwaite methods [13]. All analyses were performed using SAS software, version 9.4 (SAS Institute Inc.),
with statistical significance defined as P , .05.
3. Results
3.1. Demographics
Of the 152 ADNI participants who met the criteria for having
longitudinal CSF samples (range 2–7 LPs over 1–7 years of
follow-up [mean (SD) 5 4.0 (1.62)] and a mean [SD] LP interval of 16 [8.6] months), four were omitted from the data set due
to missing values for CSF Ab42 (via AlzBio3) required to
define baseline amyloid status (Ab1 vs. Ab2). Participants
in the final data set of n 5 148 were 38% female, between 58
and 90 years of age at the time of initial LP (mean [SD] 5 75
[7.13]), and 68% were APOE ε4-positive (Table 1). All individuals in the MCI group were classified by ADNI as “late MCI”.
As expected, baseline HP volume and EC thickness were
different among the groups (CN . MCI . AD) (P , .0001).
Performances on MMSE, ADAS11, and ADAS13 were also
as expected, with the MCI and AD groups performing worse
than the CN group (P , .0001).
When the clinical groups were dichotomized into Ab1
and Ab2 [9], neuronal injury/inflammation biomarker levels
were higher (more AD-like) in the Ab1 than those in the
Ab2 groups, both among and within each clinical group
(Table 2). Positive correlations were observed among the
injury markers at baseline, strongest among tTau, VILIP-1,
and Ng (Spearman r 5 0.798–0.853) (Supplementary
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Table 1
Study demographics
CN

MCI

AD

Characteristics

Ab2

Ab1

Ab 2

Ab1

Ab1

N
Baseline age, mean (SD)
Gender, F/M (%F)
Education, mean (SD), y
APOE ε4 allele, 6 (%1)
# CDR 0/0.5/1, n
CDR-SB, mean (SD)
MMSE, mean (SD)
ADAS11, mean (SD)
ADAS13, mean (SD)
# LP’s 2/3/4/5/6/7, n
LP interval, mean (SD), mo
LP follow-up, mean (SD, range), mo
Total EC thickness, mean (SD), mm
Total HP volume, mean (SD), mm3

35
76 (5.7)
14/21 (40)
16 (3.1)
3/32 (9)
35/0/0
0.029 (0.12)*,y,z
29.1 (1.1)*,y,z
5.3 (2.2)*,y,z
8.4 (3.5)*,y,z
0/15/7/8/5/0
17.01 (9.44)z
52.9 (19.7, 23-86)z
6.88 (0.84)*,y,z
6577 (815)*,y,z

21
76 (3.7)
10/11 (48)
16 (3.4)
9/12 (43)
21/0/0
0.024 (0.11)*,y,z
29.4 (0.9)*,y,z
7.1 (3.3)y,z
10.5 (3.9)y,z
0/8/6/4/3/0
17.55 (10.40)z
55.0 (17.0, 26-85)z
6.88 (0.95)*,y,z
6553 (886)*,y,z

18
77 (7.3)
4/14 (22)
17 (1.8)
0/18 (0)
0/18/0
1.25 (0.55)z,x,{
27.6 (1.8)z,x,{
9.9 (4.1)z,x
15.5 (5.9)z,x
0/5/10/2/1/0
16.92 (8.98)
49.8 (17.9, 24-87)z
6.32 (0.96)z,x,{
5818 (978)z,x,{

58
74 (6.5)
18/40 (31)
16 (2.8)
40/18 (69)
0/57/1
1.61 (0.85)z,x,{
26.8 (1.8)z,x,{
11.7 (5.1)z,x,{
19.5 (7.1)z,x,{
2/26/18/5/6/1
15.90 (7.92)
45.0 (18.9, 16-86)z
6.44 (0.87)z,x,{
5861 (880)z,x,{

16
74 (6.7)
11/6 (65)
15 (3.0)
13/4 (77)
0/10/6
4.24 (1.49)*,y,x,{
23.7 (1.7)*,y,x,{
18.7 (6.1)*,y,x,{
28.9 (7.4)*,y,x,{
1/9/5/1/0/0
12.73 (2.86)x,{
30.2 (10.2, 12-50)*,y,x,{
5.26 (0.82)*,y,x,{
5117 (848)*,y,x,{

Abbreviations: Ab, amyloid b status; AD, Alzheimer’s disease; ADAS 11, Alzheimer’s Disease Assessment Scale-cognitive test, version 11 (higher score is
worse performance); ADAS 13, Alzheimer’s Disease Assessment Scale-cognitive test, version 13 (higher score is worse performance); APOE, apolipoprotein E;
CDR, Clinical Dementia Rating score; CDR-SB, CDR sum of boxes; CN, cognitively normal; EC, entorhinal cortex; HP, hippocampus; LP, lumbar puncture;
MCI, mild cognitive impairment; MMSE, Mini–Mental State Examination.
*Significantly different from MCI Ab2.
y
Significantly different from MCI Ab1.
z
Significantly different from AD Ab1.
x
Significantly different from CN Ab2.
{
Significantly different from CN Ab1.

Table 1). SNAP-25 was moderately correlated with the other
injury markers (r 5 0.619–0.720), and as expected, tTau and
pTau exhibited the highest positive correlation (r 5 0.975).
Elecsys Ab42 was positively correlated with AlzBio3 Ab42
(r 5 0.869) and negatively correlated with tTau, pTau, and
SNAP-25 (r 5 20.214, 20.324 and 20.240, respectively).
YKL-40 was significantly, but weakly, correlated with the
injury markers (r 5 0.307–0.422) but not Ab42.
3.2. Patterns of neuronal injury and neuroinflammatory
markers
Participant-level CSF biomarker trajectories were plotted
for each of the five amyloid-defined clinical groups (see
Supplementary Fig. 1 for spaghetti plots). General linear
mixed models (with random intercepts/slopes at the subject
level) were then used to estimate and compare baseline
biomarker levels and within-person rates of change in the
five groups. Results adjusting for sex, APOE ε4 status, education, baseline age, and total ventricular volume are provided in
the Supplementary Text.
3.3. ElecsysÒ tTau
Baseline tTau levels were significantly elevated in the
AD1 group compared with all other groups (all P  .01)
and the MCI1 compared with the MCI2 and CN2
(P , .0001) and CN1 groups (P 5 .02) (Table 2). Longitudinally, tTau levels significantly increased in both CN (both
P , .05) and the MCI1 groups (P , .0001) (Fig. 1, Table 2).

tTau levels decreased longitudinally in the AD1 group, but
this change did not reach statistical significance (P 5 .095).
3.4. ElecsysÒ pTau
pTau levels at baseline were significantly elevated in the
AD1 compared with all other groups (all P , .01),
MCI1 compared with MCI2 and CN2 (both P , .0001)
and CN1 groups (P 5 .02), and the CN1 compared with
the MCI2 and CN2 groups (both P , .03) (Table 2). Longitudinally, pTau levels significantly increased in the CN1
(P 5 .001) and trended toward increase in the MCI1 group
(P 5 .055). Strikingly, pTau levels significantly declined in
the AD1 group (P  .0001) (Fig. 1, Table 2), with rate of
change greater than the change in all other groups (P , .001).
3.5. VILIP-1
Levels of baseline VILIP-1 were significantly higher in
the MCI1 and AD1 compared with both the MCI2 and
CN2 groups (all P  .01) (Table 2). The amyloid-positive
groups did not differ from one another (all P . .05). Longitudinally, as with pTau, VILIP-1 levels strongly and significantly decreased in the AD1 group (P 5 .006), whereas no
significant changes were observed in the other groups (Fig. 1,
Table 2).
3.6. SNAP-25
SNAP-25 values at baseline were significantly higher in
the AD1 and MCI1 compared with the CN2 (both
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Table 2
Baseline CSF biomarker levels and estimated within-person annual change over time
CN

MCI

AD

Characteristics

Ab2

Ab 1

Ab2

Ab1

Ab1

N
Baseline CSF Biomarkers
Elecsys Ab42, mean (SD), pg/mL
Elecsys tTau, mean (SD), pg/mL
Elecsys pTau, mean (SD), pg/mL
VILIP-1, mean (SD), pg/mL
SNAP-25, mean (SD), pg/mL
Ng, mean (SD), pg/mL
YKL-40, mean (SD), ng/mL
CSF Biomarker Estimated Annual Slope
Elecsys Ab42, pg/mL (SE)
P value
Elecsys tTau, pg/mL (SE)
P value
Elecsys pTau, pg/mL (SE)
P value
VILIP-1, pg/mL (SE)
P value
SNAP-25, pg/mL (SE)
P value
Ng, pg/mL (SE)
P value
YKL-40, ng/mL (SE)
P value

35

21

18

58

16

1413 (284)*,y,z
230 (70.8)y,z
20.3 (6.30)*,y,z
143.3 (44.9)y,z
4.45 (1.5)y,z
2302 (1066)y,z
384.1 (20.08)

687 (274)x,{
272 (84.9)y,z
27.4 (9.56)y,z,x,{
152.6 (49.8)
4.66 (1.4)y,z
2339 (953)z
399.6 (19.4)

1404 (318)*,y,z
215 (68.2)y,z
18.1 (5.83)*,y,z
140.5 (50.2)y,z
3.72 (1.3)y,z
1962 (945)y,z
361.6 (19.4)z

590 (187)x,{
331 (117.5)*,z,x,{
33.7 (13.62)*,z,x,{
176.7 (61.0)x,{
6.01 (2.2)*,x,{
2836 (1426)x,{
401.3 (17.87)

578 (214)x,{
407 (167.5)*,y,x,{
42.8 (19.90)*,y,x,{
185.6 (70.1)x,{
6.84 (3.3)*,x,{
3383 (1576)*,x,{
471.9 (41.86){

220.91 (5.6)
.0004k
4.29 (2.1)z
.048k
0.39 (0.2)z
.69
20.23 (1.0)z
.81
20.0453 (0.042)
.28
22.74 (26.1)z
.92
4.51 (3.5)
.20

27.96 (7.27)
.28
6.75 (2.7)z
.015k
0.88 (0.3)z,{
.013k
0.89 (1.2)z
.48
0.00279 (0.053)
.96
19.88 (33.6)z
.56
6.29 (4.3)
.15

22.38 (8.4)
.78
1.10 (3.1)
.72
0.028 (0.3)*,z
.93
20.21 (1.4)z
.88
0.00715 (0.060)
.91
15.5521 (38.2)z
.68
5.54 (4.9)
.26

27.82 (5.17)
.13
7.55 (1.8)z
,.0001k
0.35 (0.2)z
.055
20.96 (0.9)z
.27
20.0387 (0.037)
.29
238.6334 (23.6)z
.10
6.37 (3.0)
.035k

229.48 (14.2)
.039k
27.11 (4.2)*,y,x
.095
21.65 (0.4)*,y,x,{
,.0001k
26.31 (2.3)*,y,x,{
.006k
20.172 (0.088)
.05k
2232.43 (58.9)*,y,x,{
,.0001k
1.68 (7.1)
.81

Abbreviations: Ab, amyloid b status; AD, Alzheimer disease; CN, cognitively normal; MCI, mild cognitive impairment; Ng, neurogranin; pTau, phosphotau181; SNAP-25, synaptosomal-associated protein 25; tTau, total tau; VILIP-1, visinin-like protein 1.
Bold–Slope that is statistically different from zero.
NOTE. All significance at least P , .05.
*Significantly different from CN Ab1.
y
Significantly different from MCI Ab1.
z
Significantly different from AD Ab1.
x
Significantly different from CN Ab2.
{
Significantly different from MCI Ab2.
k
Statistically significant slope.

P , .0003), CN1 (P 5 .001 and P 5 .01, respectively), and
MCI2 groups (both P , .0001) (Table 2). Longitudinally,
SNAP-25 levels declined significantly in the AD1 group
(P 5 .05), whereas no significant changes were observed
in the other groups (Fig. 1, Table 2).
3.7. Ng
Baseline levels of Ng were significantly higher in the
AD1 group than the CN2 (P 5 .003), CN1 (P 5 .02),
and MCI2 (P 5 .0006) groups, although not between the
MCI1 and AD1 groups (P 5 .10) (Table 2). Levels were
also higher in the MCI1 compared with the CN2
(P 5 .004) and MCI2 (P 5 .02) groups. Longitudinally,
Ng markedly and significantly decreased in the
AD1 group (P , .0001), whereas no significant changes
were observed in the other groups (Fig. 1, Table 2).
3.8. YKL-40
In contrast to the markers of neuronal injury, baseline
levels and longitudinal patterns of change in the neuroin-

flammatory marker, YKL-40, exhibited a large degree of
within-group variability. Baseline YKL-40 was significantly
higher in the AD1 compared with the MCI2 (P 5 .04) but
not the other groups (Table 2). Longitudinally, all groups
showed an increase in mean levels over time, but this increase was statistically significant only in the MCI1 group
(P 5 .03) (Fig. 1, Table 2), perhaps due to less variability
(smaller SD) within that group.
3.9. ElecsysÒ Ab42
Although CSF Ab42 (as measured in ADNI by AlzBio3)
was used a priori to define amyloid status in the clinical
groups, we were also interested in evaluating the patterns
of this biomarker using the novel ElecsysÒ platform. As expected, baseline Ab42 levels (via ElecsysÒ) were significantly lower in all Ab1 than those in Ab422 groups (all
P , .0001) (Table 2). Longitudinally, levels decreased in
all groups (and at similar rates), although only the AD1
and CN2 groups reached statistical significance (P 5 .04
and P 5 .0004, respectively) (Fig. 1, Table 2).
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Fig. 1. Baseline concentrations and estimated within-person 5-year change in CSF biomarkers. Baseline biomarker concentrations (top, gray panel) and estimated group slopes (bottom, white panel) for Ab42 (A), tTau (B), pTau (C), VILIP-1 (D), SNAP-25 (E), Ng (F), and YKL-40 (G). Baseline is shown for each
individual, estimated group slopes of average annual change in five bins defined by diagnostic group and amyloid status are extrapolated to show 5 years of
change. A Different from CN2 group, B Different from CN 1 group, C Different from MCI 1 group, D Different from AD 1 group, E Different from
MCI- group, * Different from 0. Abbreviations: Ab; b amyloid; tTau, total tau; pTau, phospho-tau; VILIP-1, visinin-like protein 1; SNAP-25, synaptosomal-associated protein 25; Ng, neurogranin; YKL-40, chitinase-3 like-1.
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Table 3
Baseline cognitive performance and imaging measures and estimated within-person annual change over time
CN

MCI

AD

Characteristics

Ab2

Ab1

Ab 2

Ab1

Ab1

N
Baseline Cognitive and Imaging Biomarkers
MMSE, mean (SD)
ADAS 11, mean (SD)
ADAS 13, mean (SD)
Total EC thickness, mean (SD), mm
Total HP volume, mean (SD), mm3
Cognitive and Imaging Estimated Annual Slope
MMSE, points (SE)
P value
ADAS 11, points (SE)
P value
ADAS 13, points (SE)
P value
Total EC thickness, mm (SE)
P value
Total HP volume, mm3 (SE)
P value

35

21

18

58

16

29.1 (1.1)*,y,z
5.3 (2.2)*,y,z
8.4 (3.5)*,y,z
6.88 (0.84)*,y,z
6577 (815)*,y,z

29.4 (0.9)*,y,z
7.1 (3.3)*,y,z
10.5 (3.9)*,y,z
6.88 (0.95)*,y,z
6553 (886)*,y,z

27.6 (1.8)y,z,x,{
9.9 (4.1)z,x,{
15.5 (5.9)y,z,x,{
6.32 (0.96)z,x,{
5818 (978)z,x,{

26.8 (1.8)*,z,x,{
11.7 (5.1)z,x,{
19.5 (7.1)*,z,x,{
6.44 (0.87)z,x,{
5861 (880)z,x,{

23.7 (1.7)*,y,x,{
18.7 (6.1)*,y,x,{
28.9 (7.4)*,y,x,{
5.26 (0.82)*,y,x,{
5117 (848)*,y,x,{

20.051 (0.2)y,z
.76
0.20 (0.3)y,z
.52
0.37 (0.3)y,z
.27
20.0401 (0.022)*,y,z,{
.069
259.4 (14.5)*,y,z,{
.0001k

20.22 (0.2)y,z
.30
0.75 (0.4)y,z
.06
1.25 (0.4)y,z
.0042k
20.118 (0.023)y,z,x
,.0001k
2111.2 (18.2)y,z,x
,.0001k

20.039 (0.2)y,z
.87
0.30 (0.4)y,z
.50
0.53 (0.5)y,z
.27
20.118 (0.031)y,z,x
.0003k
2145.9 (20.5)y,z,x
,.0001k

21.26 (0.1)*,z,x,{
,.0001k
2.06 (0.3)*,z,x,{
,.0001k
2.43 (0.3)*,z,x,{
,.0001k
20.261 (0.018)*,x,{
,.0001k
2216.3 (11.9)*,x,{
,.0001k

22.49 (0.3)*,y,x,{
,.0001k
4.74 (0.6)*,y,x,{
,.0001k
4.98 (0.7)*,y,x,{
,.0001k
20.295 (0.057)*,x,{
,.0001k
2230.8 (36.0)*,x,{
,.0001k

Abbreviations: Ab, amyloid b status; AD, Alzheimer disease; ADAS 11; Alzheimer’s Disease Assessment Scale-cognitive test, version 11 (higher score is
worse performance); ADAS 13, Alzheimer’s Disease Assessment Scale-cognitive test, version 13 (higher score is worse performance); CN, cognitively normal;
EC, entorhinal cortex; E-pTau, Elecsys pTau181; HP, hippocampal; MCI, mild cognitive impairment; MMSE, Mini–Mental State Examination (0-30, with 30 as
perfect score).
Bold–Slope that is statistically different from zero.
NOTE. All significance at least P , .05.
*Significantly different from MCI Ab2.
y
Significantly different from MCI Ab1.
z
Significantly different from AD Ab1.
x
Significantly different from CN Ab2.
{
Significantly different from CN Ab1.
k
Statistically significant slope.

3.10. Cognitive measures
As expected, cognitive performance differed with clinical
diagnosis, particularly in the Ab1 symptomatic groups.
Furthermore, Ab1 individuals exhibited longitudinal
changes in MMSE and ADAS11/13 that are consistent
with a worsening of cognitive performance and often at a
faster rate than the Ab2 groups. See Supplementary Fig. 2
for spaghetti plots.
3.11. MMSE
Baseline MMSE was lower (indicative of worse performance) in the AD1 group than any other group (all
P , .0001), lower in the MCI1 compared with the MCI2
(P 5 .03) and both CN groups (both P , .0001), and in the
MCI2 compared with both CN groups (both P , .03)
(Table 3). In the AD1 and MCI1 groups, MMSE was
decreasing significantly (both P , .0001) and at a faster rate in
the AD1 compared with the MCI1 group (P ,.0001) (Table 3).
3.12. ADAS11 and ADAS13
At baseline, ADAS11 was significantly elevated (indicating worse performance) in the AD1 compared with

both CN groups (both P , .0001), both MCI groups
compared with both CN groups (both P , .02), and in the
AD1 compared with both MCI groups (both P , .0001)
(Table 3). Longitudinally, ADAS11 score significantly
increased in the AD1 and MCI1 groups (both P , .0001)
and at a significantly faster rate in the AD1 versus the
MCI1 group (P , .0001) (Table 3).
Baseline ADAS13 performance was similar to ADAS11
except that the MCI1 group was also significantly
elevated (worse performance) compared with the MCI2
group (P 5 .05) (Table 3). Longitudinally, ADAS13 was
significantly increasing in all three Ab1 groups (all
P , .004), at a faster rate in the AD1 compared with
the MCI1 (P 5 .0005) and CN1 (P , .0001) groups,
and at a faster rate in the MCI1 than the CN1 group
(P 5 .02) (Table 3).

3.13. Volumetric MRI measures
As expected, HP volume and EC thickness were smaller
at baseline in the AD1 than those in the other groups. However, all but the CN2 group exhibited significant atrophy
over time, albeit at different rates. See Supplementary
Fig. 3 for spaghetti plots.
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3.14. HP volume
HP volume at baseline was significantly smaller in the
AD1 compared with all other groups (P , .001 for both
CN groups; P 5 .03 for both MCI groups) and in both
MCI groups compared with the CN groups (MCI2 vs.
CN2 [P 5 .003] and CN1 [P 5 .01]; MCI1 vs. CN2
and CN1 [both P  .0007]) (Table 3). Longitudinally, all
groups exhibited significant HP shrinkage over time (all
P  .0001) (Table 3). Volume in the AD1 and
MCI1 groups decreased at a significantly faster rate than
in both CN groups (P  .003 and P  .001, respectively)
and the MCI2 group (P 5 .04 and P 5 .003, respectively).
The rate of atrophy in the MCI2 group was faster than the
CN2 group (P 5 .0009) and in the CN1 compared with
the CN2 group (P 5 .03).
3.15. Entorhinal cortex thickness
At baseline, EC thickness was significantly smaller in the
AD1 compared with all other groups (P  .0003), in the
MCI1 compared with the CN groups (P 5 .0004 for CN2
and P 5 .01 for CN1) (Table 3). MCI2 was also significantly thinner than the CN2 group (P 5 .03) and at the significance level compared with the CN1 group (P 5 .05).
Longitudinally, EC thickness was declining in all but the
CN2 group (all P  .0003) and at a faster rate in the
AD1 compared with the CN1 (P 5 .005) and MCI2
(P 5 .007) groups (Table 3). The EC in the MCI1 group
was also shrinking more quickly than the CN1 and MCI2
groups (both P  .0001).
4. Discussion
Our primary finding is the decrease over time in the concentration of several different CSF markers of neuronal
injury (Tau, pTau, VILIP-1, SNAP-25, and Ng) in individuals who had symptomatic AD. In contrast, elevations in
tTau, but not the other injury markers, were observed at
earlier stages (amyloid-positive MCI and CN groups).
Importantly, these findings replicate similar longitudinal
patterns (for tTau, pTau, and VILIP-1) reported in a small
cohort of individuals with autosomal-dominant AD [7],
thus supporting a commonality in neuropathologic processes
in sporadic and genetic forms of the disease. Interestingly,
reductions in Ab42 were observed in the CN2 group, potentially indicating amyloid deposition in the very earliest stage
of disease; other studies have shown that levels of CSF Ab42
begin to decrease before amyloid being detectable by positron emission tomography and before changes in CSF
tau(s) [20,21]. The findings are also similar to the first
published study on longitudinal (up to 2 years) Ab42,
tTau, and pTau in ADNI, which showed longitudinal
changes in pTau after changes in Ab42 [20]. Knowledge
of such within-person patterns of change has important implications for clinical trials in MCI and early stage AD in
terms of the use of biomarker concentrations as pathologic

endpoints in determining treatment efficacy for neuronal
integrity and is being studied concurrently in related groups
such as individuals with Down Syndrome [22]. Furthermore,
the combination of CSF biomarkers and other modalities
may be of use, even in the preclinical stages of disease, as
significant changes in ADAS 13 were seen in the
CN1 group.
While all the injury markers decreased over time in the
AD1 group, the reduction in Ng was especially robust. Ng
is a calmodulin-binding postsynaptic neuronal protein
[23,24] thought to be involved in activity-dependent synaptic plasticity and long-term potentiation [25]. Levels are
reduced in AD brain [26,27] and elevated in AD CSF
[12,28], with high levels predictive of progression from
MCI to AD dementia [18,29–31]. Because elevations in
CSF Ng are associated with brain atrophy [18,31] and
reduced brain glucose uptake [31], it is considered a marker
of synaptic dysfunction/loss.
Although less is known about SNAP-25 (a presynaptic tSNARE molecule that plays a crucial role in calciumdependent exocytosis of synaptic vesicles) in AD, like Ng,
levels are reduced in brain [32] and elevated in CSF [33]
compared with controls. Although both synaptic markers
were decreasing longitudinally in the AD1 group, Ng was
dropping at more than twice the rate as SNAP-25 (annual decreases of 6.9% vs. 2.5%, respectively) and the other
markers (1.8% tTau, 3.9% pTau, and 3.4% VILIP). Interestingly, Ab42 was also significantly decreasing annually by
5% in the early AD1 group but less so in the other groups.
Although levels of Ab42 are known to drop early in the disease and then plateau as amyloid continues to accumulate
[3], 63% (10/16) of individuals in the current AD group
were at very early symptomatic stages (CDR 0.5). Baseline
levels of YKL-40, an astrocyte-derived protein with presumed neuroinflammatory properties [34], also increased
with clinical severity as reported previously [35], but we
observed a high level of within-group variability in longitudinal patterns. It is likely that YKL-40 reflects neuroinflammatory components not specifically due to AD.
Interestingly, levels appeared to increase with age in the
AD1 group (Supplementary Fig. 1) as has also been
observed in CN middle-aged individuals [14]. Further
studies regarding the role of YKL-40 in neurodegenerative
diseases are warranted [36,37].
Despite the fact that there were strong positive correlations among levels of the various injury markers, consistent
with previous reports [18,38], discordance in patterns of
longitudinal change over time for tTau was observed in the
amyloid-positive MCI group (robust increases in tTau but
no statistical change in the other markers, including pTau).
CSF tTau levels are known increase in response to acute
neuronal death as occurs in response to stroke, traumatic
brain injury, and Creutzfeldt-Jakob disease [39], thus suggesting a robust phase of neuronal death and/or alterations
in the normal metabolism of tau at the very early (MCI)
symptomatic stage of AD, the time during which the first
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signs of cognitive impairment are evident. The reason(s) for
a lack of within-person increase in these other injury
markers remains unclear but may have something to do
with the relatively short follow-up time in the current cohort
(mean 4.0 6 1.61 years) and/or the lack of information
regarding how long a given individual had been in their
designated clinical group at the time of baseline LP (i.e.,
where in the natural progression of the disease), or could
conceivably be influenced by the older age of the ADNI
cohort (mean baseline age of w75 years for all groups), as
some CSF biomarkers do appear to be age related [14].
Alternatively, such discordance may indicate that these
markers reflect different processes associated with synaptic
dysfunction and/or neuronal injury [38]. A full understanding of biomarker trajectories will require serial samples being collected from an independent and larger cohort over a
long period of time as individuals progress from one disease
stage to the next.
The biological reason(s) for reductions in CSF injury
markers over time in early AD is unclear. In fact, very little
is known about the normal metabolism of these markers
that would lead to their appearance in the CSF in both normal
and pathological settings. Although it is conceivable that such
reductions reflect a dilution of CSF analytes that would come
with increasing ventricular volume associated with overall
brain atrophy, reductions were still observed after controlling
for ventricular volume (see Supplementary Text). It is
possible that longitudinal reductions from an elevated baseline during early AD reflect a slowing of acute neurodegenerative processes with symptomatic disease progression and/or
neuronal death, leading to a smaller number of neurons that
remain and contribute to the pool in CSF. Unlike structural
MRI and amyloid (and tau) positron emission tomography
imaging measures that reflect cumulative change over the
course of the disease, CSF measures reflect a snapshot in
time, thus measuring different things. Indeed, HP and EC atrophy continued over the course of the disease even in the face
of decreasing levels of injury markers in the CSF. It is therefore not unexpected that there exists some discordance when
defining biomarker positivity (and notably for neuronal
injury), as a function of imaging versus CSF [40]. This issue
is important to consider when selecting biomarker modalities
(CSF and/or imaging) for use in screening and/or outcome
measures in clinical trials.
This study is not without limitations. The cohort with longitudinal CSF samples available for analysis was relatively
small which, when divided into five groups, may limit statistical power to detect longitudinal changes, especially in the preclinical and early symptomatic AD groups, as well as influence
the large variability seen when modeling longitudinal slopes.
The distribution of males and females was also skewed in
this cohort, with roughly 62% of participants being male.
Although serial LP follow-up was longer than that in some previous longitudinal ADNI CSF studies [41,42], it was still
relatively short (3–5 years). Also, despite the groups being
dichotomized as amyloid-positive versus -negative to ascer-
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tain plaque status in the clinical groups, there was considerable
overlap in clinical and biomarker patterns between individuals, especially in the MCI and AD groups. Finally, due to
the small numbers of individuals in the clinical/biomarker
groups and the unique biological traits captured by the
different biomarkers that may contribute independently to
the overall disease process, statistical models were not
adjusted rigorously for multiple comparisons. However, this
approach could potentially result in inflated type I errors, so
interpretation should be made with caution.
5. Conclusions
The present results underscore the importance of evaluation of true longitudinal, serial measures of CSF biomarkers
from individuals as they progress through the normal course
of the disease as opposed to the more traditional approach of
inferring longitudinal change by comparing cross-sectional
data from groups of individuals at different disease stages.
Indeed, concentrations of each of the markers have been reported to be elevated in AD compared with MCI and CN
controls [35]. While we also observed such elevations in
baseline levels of these injury markers among the different
clinical/amyloid groups, the within-person patterns of
change over time were different. For clinical trial purposes,
given the stage-specific differences in the direction of true
longitudinal change in these biomarkers, a “positive”
biomarker outcome would be different depending on the
characteristics of the trial cohort. For example, a slowing
of the course of neuronal injury may be indicated by a slowing of the rate of increase in CSF tau in individuals who are
early in the disease process (MCI), but perhaps a stabilization or even a slowing or reversal of the downward trajectory
later in the disease (mild AD), potentially reflected as a longitudinal increase or as no decrease in this marker. Such possibilities warrant consideration in clinical trial design.
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RESEARCH IN CONTEXT

1. Systematic review: The authors reviewed the literature using PubMed. Alzheimer’s disease biomarkers
have been instrumental in understanding Alzheimer’s disease as a continuum in which pathologies begin to develop 10–20 years before
dementia onset. As clinical trials of potential
disease-modifying therapies are focusing on early
disease stages, elucidating within-person biomarker
change over time is critical for defining where individuals fall along the disease cascade. Crosssectional studies report increases in neuronal injury
markers in cerebrospinal fluid with increasing
symptom severity, assessments of longitudinal
change within individuals are scarce.
2. Interpretation: Our findings of within-person reductions over time in several neuronal injury markers
in early symptomatic Alzheimer’s disease will likely
have an impact on interpretation of biomarker outcomes in clinical trials, and thus, should be considered in trial design.
3. Future directions: Evaluation of within-person
change in cerebrospinal fluid biomarkers in a
larger, independent cohort that has longer follow-up
is needed to confirm our findings.
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